SWOG clinical trial number
SWOG-8897

Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-up Study in Low-Risk Node Negative Patients (to initially low risk patients)

Closed
Phase
Accrual
100%
Published
Abbreviated Title
CMF vs. CAF ± Tamoxifen in High-Risk, Node Neg.
Activated
07/15/1989
Closed
02/01/1993

Research committees

Breast Cancer

Treatment

Tamoxifen CAF CMF

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2016

Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG S8897 trial

V Larsen;W Barlow;JJ Yang;Q Zhu;S Liu;LF Hutchins;S Kadlubar;K Albain;RB Livingston;JM Rae;I-T Yeh;PM Ravdin;S Martino;A Lyss;CK Osborne;G Hortobagyi;DF Hayes;CB Ambrosone;S Yao American Association for Cancer Research Annual Meeting (April 16-20, 2016, New Orleans, LA), abst #2032, poster

Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)

H Pan;R Gray;C Davies;J Bergh;K Pritchard;M Dowsett;DF Hayes Journal of Clinical Oncology 34, 2016 (suppl; abstr 505); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral

2014

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2010

Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMC3058716; PMID21169260]

S Yao;W Barlow;K Albain;JY Choi;H Zhao;R Livingston;W Davis;J Rae;IT Yeh;L Hutchins;P Ravdin;S Martino;A Lyss;CK Osborne;M Abeloff;G Hortobagyi;DF Hayes;C Ambrosone Clinical Cancer Research 16:6169-6176;

Manganese superoxide dismutase polymorphism treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMID 20309628; PMC2968705]

S Yao;W Barlow;K Albain;JY Choi;H Zhao;R Livingston;W Davis;J Rae;IT Yeh;L Hutchins;P Ravdin;S Martino;A Lyss;CK Osborne;M Abeloff;G Hortobagyi;DF Hayes;C Ambrosone Breast Cancer Treatment and Research 124(2):433-439;

2009

Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]

D Hershman;J Unger;W Barlow;L Hutchins;S Martino;CK Osborne;RB Livinsgton;KS Albain Journal of Clinical Oncology 27(13):2157-2162

Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for breast cancer: results from an ancillary study to Southwest Oncology Group Trial S8897 (INT-0102). [PMC2799053;PMID19752340]

CB Ambrosone;W Barlow;W Reynolds;RB Livingston;IT Yeh;JY Choi;W Davis;JM Rae;L Tang;L Hutchins;PM Ravdin;S Martino;CK Osborne;M Abeloff;AP Lyss;DF Hayes;KS Albain Journal of Clinical Oncology 27(30):4973-4979

Nitric oxide synthase (N0S3) variants and breast cancer survival in a cooperative group trial (SWOG S8897) [PMC2745926; PMID19671875]

J-Y Choi;WE Barlow;KS Albain;C-C Hong;JG Blanco;RB Livingston;W Davis;JM Rae;I-T Yeh;LF Hutchins;PM Ravdin;S Martino;AP Lyss;CK Osborne;M Abeloff;DF Hayes;CB Ambrosone Clinical Cancer Research, 15(16):5258-66, 2009;

2008

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group (SWOG) protocol S8897 [PMID 18227530]

PA Ganz;MA Hussey;CM Moinpour;JM Unger;LF Hutchins;SR Dakhil;JK Giguere;JW Goodwin;S Martino;KS Albain Journal of Clinical Oncology 26:1223-1230

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2006

Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a Southwest Oncology Group intergroup trial (INT-0102)

CB Ambrosone;W Barlow;IT Yeh;DF Hayes;W Davis;JM Rae;LF Hutchins;RB Livingston;PM Ravdin;S Martino;K Osborne;M Abeloff;AP Lyss;KS Albain Breast Cancer Research and Treatment 100(Suppl 1):S18 (#37); oral presentation at SABCS

Outcome of African American women with breast cancer in cooperative group clinical trials

JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands

Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897

D Hershman;J Unger;W Barlow;L Hutchins;S Martino;M Abeloff;L Norton;R Livingston;CK Osborne;K Albain San Antonio Breast Cancer Symposium Proceedings #3049

2005

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102

LF Hutchins;SJ Green;PM Ravdin;D Lew;S Martino;M Abeloff;AP Lyss;C Allred;SE Rivkin;CK Osborne Journal of Clinical Oncology 23(33):8313-8321

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.

LJ Pierce;LF Hutchins;SR Green;DL Lew;JR Gralow;RB Livingston;CK Osborne;KS Albain Journal of Clinical Oncology 23(1):24-29

2001

Adjuvant therapy for very young women with breast cancer: need to tailored treatments

A Goldhirsch;RD Gelber;G Yothers;RJ Gray;S Green;J Bryant;S Gelber;M Castiglione-Gertsch;AS Coates Journal of the National Cancer Institute Monographs No.30:44-51

1999

CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results

L Hutchins;S Green;P Ravdin;D. Lew;S Martino;M Abeloff;A Lyss;C Henderson;C Allred;S Dakhil;I Pierce;W Goodwin;J Caton;S Rivkin;R Chapman;K Osborne 22nd Annual San Antonio Breast Cancer Symposium :#1

1998

CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.

L Hutchins;S Green;P Ravdin;D Lew;S Martino;M Abeloff;A Lyss;C Henderson;C Allred;S Dakhil;I Pierce;W Goodwin;J Caton;S Rivkin;R Chapman;K Osborne Proc of the American Society of Clinical Oncology 17:1a(#2)

A study of the late cardiac effects of two different adjuvant chemotherapy regimens in women with node negative breast cancer treated on SWOG 8897.

PA Ganz Susan G. Koman Brst Ca Foundation Symp Rpt of Grants Awarded 30:

1996

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.

KS Albain;SR Green;AS Lichter;LF Hutchins;WC Wood;IC Henderson;JN Ingle;J O'Sullivan;CK Osborne;S Martino Journal of Clinical Oncology 14(11):3009-3017

1994

The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.

A Lichter;S Green;K Albain;L Hutchins;S Martino ASCO 13:62(#51)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7436

Combined Modality Therapy of Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
01/09/1975
Closed
07/18/1979
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
07/16/1979
Closed
08/01/1989
Accrual
100%
Closed
Phase
III
Published